ST. LOUIS—July 22, 2008--GenoMed (OTC Pink Sheets GMED), the Public Health Company™, announced today that its CEO, David Moskowitz MD, has been invited to speak at the Ehlers-Danlos National Foundation learning conference to be held July 31st-August 2nd in Houston, TX (http://www.ednf.org/index.php?option=com_content&task=view&id=1475&Itemid=88889046).
Said Dr. David Moskowitz, GenoMed's CEO, "It's a great honor for me to be asked to speak at the Ehlers-Danlos national conference. Ehlers-Danlos is a so-called 'orphan disease.' It's very rare, caused by a mutation in one of the collagen genes. It's one of the best-known diseases, but still lacks any treatment. In fact, we studied it in our 'Molecular Medicine' course 30 years ago in medical school. It's exciting to have a potential treatment for this disease."
Dr. Moskowitz continued by saying, "Although Ehlers-Danlos is rare, bulges in large blood vessels—aneurysms--are quite common. Other than surgery, there's no acceptable drug treatment. I think GenoMed may have one."
Dr. Moskowitz ended by saying, "There's an excellent chance that angiotensin converting enzyme, or ACE, is the critical step in the formation of all aneurysms. I'd love to be able to show this with Ehlers-Danlos patients."
About GenoMed
GenoMed is a Next Generation Disease Management company. Unlike First Generation DM companies that rely on consensus-based guidelines that are already one or two decades old, GenoMed constantly does its own research to improve patient outcomes. The use of specific ACE inhibitors at specific doses to delay hardening of the arteries is covered by pending patents owned by GenoMed.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact:
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9938
dwmoskowitz@genomed.com
